<DOC>
	<DOCNO>NCT00661544</DOCNO>
	<brief_summary>1 . To evaluate toxicity safety combination arsenic trioxide ascorbic acid high-dose Melphalan patient multiple myeloma 2 . To evaluate efficacy combination arsenic trioxide ascorbic acid high-dose Melphalan patient multiple myeloma 3 . To determine effect arsenic trioxide melphalan pharmacokinetics</brief_summary>
	<brief_title>Arsenic Trioxide With Ascorbic Acid Melphalan Myeloma Patients</brief_title>
	<detailed_description>Treatment : High-dose melphalan follow transplant autologous stem cell think one effective way treat multiple myeloma . However , number one cause treatment failure patient disease come back . High-dose melphalan use multiple myeloma two decade consider standard care disease . Recent research laboratory clinical trial show Arsenic trioxide effective treatment multiple myeloma . It lead tumor cell death myeloma cell line myeloma patient . Arsenic trioxide also make melphalan effective antimyeloma agent . This research also show vitamin C enhance anti-myeloma activity arsenic trioxide make toxic myeloma cell . The purpose study learn combination arsenic trioxide , vitamin C , melphalan safe , well-tolerated effective myeloma patient . Before treatment begin , several test perform study status disease begin take study medication . You bone marrow aspirate biopsy . An aspirate drawing liquid marrow syringe , biopsy removal small core bone hollow needle . Aspirate do hip bone chest , biopsy always hip bone . You cytogenic test , see genetic abnormality DNA . You bone survey do , doctor look X-rays bone myeloma-related bone change . You routine specialize blood test do ( 2 tablespoon ) , measure blood count , platelet , blood clotting , kidney function , electrolyte count , level disease blood . You also urine test measure level myeloma urine . You pulmonary function test , check lung strong enough withstand high-dose chemotherapy . You initial electrocardiogram ( EKG ) also MUGA scan measure strong heart function . Women able child must negative blood pregnancy test participate study . If agree eligible , assign receive one 3 arm . In first arm melphalan vitamin C , Arsenic trioxide give . In second third arm , dose arsenic trioxide together Vitamin C melphalan give . Not patient study get dose arsenic . Your dose assignment depend experience patient combination . The first 3 patient study get low dose arsenic trioxide . Arsenic trioxide give needle vein period 2 hour , day 7 day . At time , vitamin C give day vein 7 day . On last 2 day arsenic trioxide treatment , melphalan give vein one hour arsenic . You stem cell reinfused 2 day last dose melphalan . Some patient agree optional procedure receive one dose melphalan start arsenic . You receive standard inpatient outpatient transplant care test . This involve blood bone marrow test , heart test , lung test x-ray study drug treatment transplant . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Blood test ( two tablespoon ) draw least week first month transplant , every month next 3 month . Bone marrow biopsy test check level myeloma protein urine blood also perform 3 , 6 12 month transplant . You take study one year transplant , disease come back . Patients study still return routine post-transplant follow visit decide transplant physician . If disease come back intolerable side effect occur , take study . This investigational study . Both arsenic trioxide melphalan commercially available approve use patient myeloma , though use together vitamin C investigational . About 32 patient expect participate study . All enrol UTMDACC .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>1 . Patients Multiple Myeloma follow disease category : ) Primary Refractory Disease b ) Consolidation partial remission ( defined decrease continue presence monoclonal protein serum urine immunofixation electrophoresis , and/or presence plasmacytosis bone marrow aspirate biopsy ) c ) All patient relapse prior therapy . 2 . Age 70 year . 3 . Zubrod Performance Status ( PS ) &lt; 2 . 4 . Left ventricular ejection fraction &gt; 40 % . No uncontrolled arrhythmias symptomatic cardiac disease . 5 . Forced vital capacity ( FVC ) ; Forced expiratory volume 1 second ( FEV1 ) , force vital capacity ( FVC ) Carbon Monoxide Diffusing Capacity ( DL CO ) &gt; 40 % . No symptomatic pulmonary disease . 6 . Serum bilirubin &lt; 2 time upper limit normal , SGPT &lt; 4 time upper limit normal . No evidence chronic active hepatitis cirrhosis . No effusion ascites &gt; 1L prior drainage . 7 . HIVnegative . 8 . Patient pregnant . 9 . Patient guardian able sign inform consent . 10 . Corrected QT interval le 500 msec . 1 . Corrected QT interval great 500 msec 2 . Patients complete remission ( define absence monoclonal protein serum urine immunofixation electrophoresis , absence plasmacytosis bone marrow aspirate biopsy ) . 3 . Patients nonsecretory myeloma .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Vitamin C</keyword>
	<keyword>Arsenic Trioxide</keyword>
	<keyword>Trisenox</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Autologous Stem Cell Transplant</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>